Reviews
Review: T-Cell-Engaging Bispecifics Show Ocular Events but No Class-Wide Toxicity
Abdulrahman AlhadlagOcular immunology and inflammation

A narrative review evaluating published case reports, clinical series, clinical trial safety findings, pharmacovigilance data, and U.S. Food and Drug Administration (FDA) communications examined ocular adverse events associated with T-cell-engaging bispecific therapies across hematologic and solid malignancies. Documented clinical presentations include uveitis and sclerouveitis during teclistamab therapy, orbital inflammation during xaluritamig treatment, and orbital tumor pseudoprogression during elranatamab treatment. Additionally, a pharmacovigilance analysis of mosunetuzumab identified three uveitis reports among 1,154 primary-suspect reports, and uveitis was reported in a clinical trial evaluating mosunetuzumab in combination with polatuzumab vedotin. FDA surveillance has further identified uveitis as a potential safety signal for both teclistamab and elranatamab.
The review notes that while ocular inflammatory events have been documented, their true incidence, causality, and underlying mechanisms remain uncertain, and the existing literature does not establish a class-wide ocular toxicity syndrome. In patients presenting with visual symptoms during therapy, key differential diagnoses include infection, malignant infiltration, cytokine-associated edema, and neurologic etiologies. The authors recommend clinical vigilance, prompt ophthalmic assessment for new ocular complaints, and multidisciplinary collaboration between oncologists and ophthalmologists. Standardized monitoring protocols, corticosteroid management strategies, and criteria for therapy rechallenge remain areas requiring further prospective investigation.
Key Takeaways
- FDA surveillance has identified uveitis as a potential safety signal for teclistamab and elranatamab, alongside documented clinical reports of uveitis and sclerouveitis with teclistamab, orbital inflammation with xaluritamig, and orbital tumor pseudoprogression with elranatamab.
- A pharmacovigilance analysis of mosunetuzumab identified three uveitis reports among 1,154 primary-suspect reports, with uveitis also reported in a clinical trial evaluating mosunetuzumab combined with polatuzumab vedotin.
- Current evidence does not establish a class-wide ocular toxicity syndrome, but authors recommend prompt ophthalmic evaluation of new ocular symptoms and multidisciplinary collaboration between oncologists and ophthalmologists.
Read the original sourceOcular immunology and inflammation
